Industry uses of human pluripotent stem cells

Speakers
  • Senior Scientist, Amgen
    Biography
      Stuart Chambers received his Ph.D. from Baylor College of Medicine in the lab of Margaret A Goodell in studying hematopoietic stem cell biology and gene therapy. His postdoctoral work was conducted in the lab of Lorenz Studer identifying methods to neuralize pluripotent stem cells for the purposes of creating neurons for use in cell therapy and induced pluripotent stem cell disease modeling. His cell therapy work was continued as a Scientist when he joined start-up company Neurona Therapeutics. He now works at Amgen as a Senior Scientist in Discovery Research within the Genome Analysis Unit and is tasked with using pluripotent stem cell derived cell fates for target identification, human disease modeling, and drug development.

    Abstract:

    Human pluripotent stem cells (hPSCs) and their derivatives are increasingly being used in industry to gain a competitive edge in drug discovery and a new wave of biotechnology start-up companies are poised to evaluate hPSC-derived cell therapies.  Over the past decade protocols to a broad repertoire of hPSC-derived cell fates have been identified and published differentiating pluripotent stem cells to generate cells more capable of recapitulating phenotypes seen in primary cells.  Although, commercial uses for these cells are quite similar to academics on the day-to-day, there are stark differences in how industry plans to use pluripotent tissue.  Seen through the lens of industry, approaches to high throughput screening, how one employs disease modeling, and the overall need for greater scale and reproducibility become greater priorities.

    Worldwide hPSC-derived cells are being evaluated in clinical trials, and with great enthusiasm within the United States several industry and academic efforts are underway to determine if a cure can be found.  These endeavors further underscore the importance of keeping the technical limitations of hPSCs and their derivatives in mind.  Numerous hurdles still remain before cells can make it to the clinic.  Cells will have to be thoroughly vetted for safety, engineering solutions need to be identified for large-scale production, and protocols require adaptation to adhere to good manufacturing practices.  Even then, limitations remain as to appropriate disease indications for cellular therapies.


    Show Resources
    You May Also Like
    MAY 22, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 22, 2018 08:00 AM PDT
    DATE: May 22, 2018TIME: 08:00AM PDT The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that...
    MAY 03, 2018 11:00 AM PDT
    MAY 03, 2018 11:00 AM PDT
    DATE: May 3, 2018TIME: 11:00AM PDT, 2:00PM EDTWhile stress is one of the leading causes of neuropsychiatric disorders, the molecular underpinnings of how stress induces alterations in b...
    APR 27, 2018 10:00 AM PDT
    C.E. CREDITS
    APR 27, 2018 10:00 AM PDT
    DATE: April 27, 2018TIME: 10:00am PST, 1:00pm ESTGlioblastoma (GBM) and Medulloblastoma (MB) are the most common adult and paediatric brain tumours, both of which can have devastating c...
    AUG 15, 2018 08:00 AM PDT
    C.E. CREDITS
    AUG 15, 2018 08:00 AM PDT
    DATE: August 15, 2018TIME: 08:00AM PDT, 11:00AM EDTThe failure of current chemotherapeutic strategies in the fight against cancer can be largely attributed to the occurrence of drug res...
    JUN 29, 2018 09:00 AM PDT
    C.E. CREDITS
    JUN 29, 2018 09:00 AM PDT
    DATE: June 29, 2018TIME: 09:00AM PDT, 12:00PM EDT There is significant epidemiological evidence to suggest that the consumption of a high-broccoli diet is associated with a r...
    MAY 24, 2018 09:00 AM PDT
    C.E. CREDITS
    MAY 24, 2018 09:00 AM PDT
    Recent advances in immuno-oncology research has proven the critical role of immune cells in cancer therapy. Deep understanding of the interaction and phenotype of immune and tumor cells withi...
    Loading Comments...